( e following location:

http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey ={188066EA-1D6A-4A42-A0B8-0E27B5DA8D33}&SKey={F80F5B70-96B7-4FF9-A8FF-96 3E225CBA20}&MKey={E3F4019C-0A43-4514-8F66-B86DC90CD935}&AKey={728BCE9C-1 21B-46B9-A8EE-DC51FDFC6C15} <http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKe y=%7b188066EA-1D6A-4A42-A0B8-0E27B5DA8D33%7d&SKey=%7bF80F5B70-96B7-4FF9- A8FF-963E225CBA20%7d&MKey=%7bE3F4019C-0A43-4514-8F66-B86DC90CD935%7d&AKe y=%7b728BCE9C-121B-46B9-A8EE-DC51FDFC6C15%7d>

About Santaris Pharma

Santaris Pharma is a clinical-stage biopharmaceutical company focused on developing a new class of RNAi drugs intended to switch off the expression of harmful genes. Called RNA Antagonists, these new drugs are being developed by Santaris and its corporate partners for the treatment of cancer and metabolic disorders. Created in May 2003 and backed by a broad group of leading international life science venture capital investors, Santaris Pharma completed a Euro 40m second round of equity financing in May 2006. In July 2006, the Company entered into a global partnership with Enzon Pharmaceuticals of New Jersey to co-develop and commercialise a series of Santaris RNA Antagonists for improving the treatment of cancer.

Santaris Pharma's RNA Antagonist drug pipeline is based on its unique Locked Nucleic Acid (LNA) technology. LNA drugs, with their high potency and biostability, have the potential to transform the field of RNAi medicines, making specific and effective gene silencing a reality in human medicine. If this potential is realised, even in part, it may be possible to design new drugs to treat the underlying genetic causes of disease rather than just the physical s
'"/>